Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 4/20 | 1.00 |
| ▸ | JAK1 | P23458 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514963 | 0.95 | TYK2 (1.00) | TYK2JAK2JAK1CDK9JAK3 | |
| SCHEMBL3513787 | 0.95 | TYK2 (1.00) | TYK2JAK2JAK1CDK9JAK3 | |
| SCHEMBL3513725 | 0.94 | TYK2 (0.98) | TYK2JAK2JAK1CDK9JAK3 | |
| SCHEMBL3544923 | 0.92 | TYK2 (0.84) | TYK2JAK2JAK1CDK9JAK3 | |
| SCHEMBL3512516 | 0.92 | TYK2 (0.84) | TYK2JAK2JAK1CDK9JAK3 | |
| SCHEMBL3582616 | 0.92 | TYK2 (0.84) | TYK2JAK2JAK1CDK9JAK3 | |
| SCHEMBL12990018 | 0.91 | TYK2 (0.87) | TYK2JAK2JAK1CDK9JAK3 | |
| SCHEMBL1707038 | 0.91 | TYK2 (0.84) | TYK2JAK2JAK1CDK9JAK3 | |
| SCHEMBL12989394 | 0.91 | TYK2 (0.83) | TYK2JAK2JAK1CDK9JAK3 | |
| SCHEMBL3536222 | 0.90 | TYK2 (0.82) | TYK2JAK2JAK1CDK9JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590700-A1 | TREATING SKIN IRRITATION FROM APPLICATION OF AN ALTERNATING ELECTRIC FIELD | Novocure GmbH (CH) | 2025-07-30 | — | — | EP | disclosed |
| CN-119907806-A | Treatment of skin irritation caused by application of alternating electric fields | 诺沃库勒有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2024062457-A1 | TREATING SKIN IRRITATION FROM APPLICATION OF AN ALTERNATING ELECTRIC FIELD | NOVOCURE GMBH (CH) | 2024-03-28 | — | — | WO | disclosed |
| US-20240101661-A1 | TREATING SKIN IRRITATION FROM APPLICATION OF AN ALTERNATING ELECTRIC FIELD | NOVOCURE GMBH (CH) | 2024-03-28 | — | — | US | disclosed |
| EP-4066831-A1 | PHARMACEUTICAL COMPOUNDS | Sareum Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| EP-3528806-B1 | PHARMACEUTICAL COMPOUNDS | SAREUM LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022068933-A1 | COMPOUNDS AND METHODS OF TREATING DISEASES | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-07 | — | — | WO | disclosed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | TYK2 66/4885JAK2 2/4885JAK1 1/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | TYK2 21/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.